Uterine Fibroids Treatment Market

SKU: DMPH8 | Last Updated On: Aug 30 2022 | Available Formats

> Uterine Fibroids Treatment Market Expected to reach a high CAGR of 4.4% during the forecast period 2022-2029

Uterine Fibroids Treatment Market is segmented By Treatment Type (Hormone therapy, Androgens, Gonadotropin-releasing hormone agonists, Uterine artery embolization, Myomectomy, Hysterectomy), By Type (Submucosal, Subserosal, Intramural, Pedunculated, blood clots, ulipristal acetate),  By End User (Hospitals, ASCs, Wound Care Centers, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029

Uterine Fibroids Treatment Market Size Growth Rate Insights 2022-2029

Uterine Fibroids Treatment Market size was valued at USD 1,280.20 million in 2021 and is estimated to reach a compound annual growth rate (CAGR) of 4.10% over the forecast period 2022 to 2029. Uterine Fibroids are the most commonly benign, non-cancerous tumors of a woman’s uterus, most often seen during the childbearing years. Fibroids are only treated if they cause symptoms and treatment options to range from medications to invasive surgery. The Uterine Fibroids Treatment market has significant opportunities to grow. The global uterine fibroids treatment market is primarily driven by an increasing patient pool owing to the increasing female geriatric population, the growing prevalence of hormonal disorders, and changing lifestyles. Around 700,000 women in seven major market countries have symptoms severe enough to require surgery or radical treatment.

Major growth drivers of the uterine fibroids treatment market over the globe are an increase in consciousness among individuals about diseases, growth of efficient and new technology, rising government activities over the globe, a surge in occurrence of uterine fibroids, and alter in people’s lifestyle, and increasing number of women of reproductive age. Furthermore, rise in acceptance of treatment of uterine in developing countries such as India, China, and other economies, they will produce new opportunities for the global market for uterine fibroid treatment. Though, there are few elements hampering the growth of the global uterine fibroids treatment market are huge expensive of research and developments, and a lack of expertized professionals are major restraints for the uterine fibroid treatment.

Among all regions, such as Europe, Asia Pacific, Latin America, and the Middle East and Africa, the North America Uterine Fibroids Treatment Market controlled the global market over the forecast period, due to the large number of patients suffering from the uterine fibroid issue, heavy medical claims reimbursement initiatives, and advanced technologies in uterine fibroid treatment. Asia Pacific uterine fibroids treatment market is anticipated to reach the fastest growth rate, due to quickly growing women population, increase in awareness, supportive government policies, upgrade of healthcare infrastructure and increasing medical tourism industry in emerging countries such as India, and China in the Asia Pacific region. 

Uterine Fibroids Treatment Market Growth Dynamics

The global uterine fibroids treatment market growth is driven by the increase in consciousness among individuals about diseases, growth of efficient and new technology, rising government activities over the globe, a surge in occurrence of uterine fibroids and alter in people’s lifestyles, and increased number of women of reTreatment Typeive age.

Rising incidences of uterine fibroids drive the market growth

Uterine fibroids are the most common pelvic tumors in women, occurring globally with a prevalence of 21.4%. Uterine leiomyomas are one of the most common and yet understudied diseases in women. According to the International Federation of Gynecology and Obstetrics, 2020 data,  these tumors, commonly known as fibroids, affect women mainly during their reTreatment Typeive years and are diagnosed in up to 70% of white women and more than 80% of women of African ancestry during their lifetime. This disease has a profound impact on health care delivery and costs worldwide. Though most women with fibroids are asymptomatic, approximately 30% of them will present with severe symptoms which can include abnormal uterine bleeding, anemia, pelvic pain and pressure, back pain, urinary frequency, constipation, or infertility, and will require intervention. In the United States, every year, approximately 6.5 million women seek treatment for fibroids, and nearly 1/3 of employed patients (28%) report missing days of work due to fibroid symptoms.

Low awareness of treatment options will hamper the growth of the market

However, limited attention on fibroids in both society and the medical community means that at-risk women do not have access to the information they need about the disease. The 2020 study in the Journal of Women’s Health found that only 49% of at-risk women, those who had symptoms suggestive of fibroids but not a clinical diagnosis had heard of uterine fibroids. Following the onset of their symptoms, most of these women (60%) tried to manage symptoms themselves or waited to see if the symptoms went away (50%). Even when women do receive the diagnosis of a fibroid, their treatment options are limited and often affect their fertility. To relieve pain associated with uterine fibroids, women can take over-the-counter acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs), but these are just temporary fixes for pelvic pain. Some forms of birth control can help alleviate heavy bleeding but don’t work for all women and are not an option for women trying to get pregnant.

Uterine Fibroids Treatment Market Scope

Metrics

Details

Market CAGR

4.4%

Segments Covered

By Treatment Type, By Type, By End User, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

To know more insights into the Market, Download Our Sample Brochure

COVID-19 Impact Analysis

According to the article published in 2021 in Gynecological Laparoscopic Surgery in the Era of the COVID-19 Pandemic: A Prospective Study, a joint statement published by the Association of Ancillary Endoscopic Surgeons by The American College of Obstetricians and Gynecologists (AAGL), has recommended the suspension of elective surgery, shifting the focus to emergency surgery and oncology. The COVID-19 pandemic is having a significant impact on gynecological surgery. The American College of Surgeons has recommended delaying all unnecessary invasive surgery by March 2020. According to a December 2021 research paper titled Analysis of response and effects impact of COVID-19 on gynecological surgery in major university hospitals,  1,545 gynecologic cases were done in 2019, compared to 942 cases in 2020, suggesting a 39.0% decline.

Uterine Fibroids Treatment Market Segmentation Analysis

The surgical methods segment is expected to grow at the fastest CAGR during the forecast period 2022-2029

The surgical methods segment accounts for the largest market share in 2021. Medications can help if the symptoms are mild. However, doctors usually recommend procedures for women whose fibroids cause moderate or severe symptoms, like pain or heavy bleeding.  Surgery to treat uterine fibroids can include organ preservation or involve partial or total organ removal. Three different approaches (abdominal, laparoscopic, vaginal) or a combination of the three are used for the surgical treatment of uterine fibroids. Several types of surgical procedures are performed for the treatment of uterine fibroids. Dome of them includes endometrial Ablation, MRI Guided Procedures, Hysterectomy, Myomectomy, Uterine Artery Embolization (UAE), and Radiofrequency Ablation, among others. Among these, Hysterectomy accounted for the largest market share in 2021. 

Uterine Fibroids Treatment Market Geographical Analysis

North America region holds the largest market share of the Global Uterine Fibroids Treatment Market  

North America dominates the market for uterine fibroids treatment and is expected to show a similar trend over the forecast period. North America has been the largest market for uterine fibroid treatment, owing to its established healthcare industry, particularly in the U.S. and Canada, increased awareness, and easy accessibility to advanced technologies. The increased patient pool undergoing hormonal disorders and increasing prevalence of uterine cancer is the key growth driving factor for this regional uterine fibroid treatment market. For instance, in the USA, the prevalence of uterine fibroids was 60% at the age of 35, which increased to more than 80% by the age of 50 years among women.

Moreover, the advent of minimally invasive and effective alternatives to open surgeries, technological advancements, and, frequent Treatment Type innovations coupled with an increase in regulatory approvals and favorable reimbursement policies are expected to boost the growth of the market in the region.

Uterine Fibroids Treatment Market  - Competitive Landscape

The Uterine fibroids treatment market is a moderately competitive presence of local as well as global companies.  Some of the key players which are contributing to the growth of the market are Boston Scientific Corporation (Minerva Surgical), Cooper Surgical, Inc., Olympus Corporation, Acessa Health (Halt Medical, Inc.), Gynesonics, Conmed Corporation, AbbVie Inc., Medtronic, Karl Storz, Richard Wolf GmbH, LiNA Medical USA, Blue Endo among others. The major players are adopting several growth strategies such as Treatment Type launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance, on May 12, 2020, Minerva Surgical, Inc, acquired the following Intrauterine Health Treatment Types from Boston Scientific: the Symphion Tissue Removal System; the Resectr Tissue Resection Device; and the Genesys HTA System.

Boston Scientific Corporation

Overview:

The company was founded in 1979. It has headquarters in the United States. Boston Scientific Corporation develops, manufactures, and markets minimally invasive medical devices. The Company's Treatment Types are used in interventional cardiology, cardiac rhythm management, peripheral interventions, electrophysiology, neurovascular intervention, endoscopy, urology, gynecology, and neuromodulation.    

Treatment Type Portfolio:

Symphion Tissue Removal System:  The all-in-one Symphion System is designed to transform the way you remove uterine tissue. It unites breakthrough fluid management, direct intrauterine pressure monitoring, and bladeless resection to work together in perfect harmony. 

The global uterine fibroids treatment market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.  

Trending Topics

Menopause Treatment Market

Remote Patient Monitoring Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report



Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest